Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Catarina Falcão de Campos & Isabel Conceição. (2023) Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy. Drug, Healthcare and Patient Safety 15, pages 51-62.
Read now
Read now
Madeline Merkel, David Danese, Chongshu Chen, Jessie Wang, Aozhou Wu, Hongbo Yang & Hollis Lin. (2023) Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy 24:10, pages 1205-1214.
Read now
Read now
Maria C. Azevedo Coutinho, Nuno Cortez-Dias, Guilhermina Cantinho, Susana Gonçalves, Miguel Nobre Menezes, Tatiana Guimarães, Gustavo Lima da Silva, Ana Rita Francisco, João Agostinho, Laura Santos, Isabel Conceição & Fausto J. Pinto. (2020) The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid 27:3, pages 174-183.
Read now
Read now
Morie A. Gertz, Morton Scheinberg, Márcia Waddington-Cruz, Stephen B. Heitner, Chafic Karam, Brian Drachman, Sami Khella, Carol Whelan & Laura Obici. (2019) Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology 12:8, pages 701-711.
Read now
Read now
Isabel Conceição, Teresa Coelho, Claudio Rapezzi, Yeşim Parman, Laura Obici, Lucía Galán & Antoine Rousseau. (2019) Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid 26:3, pages 103-111.
Read now
Read now
Violaine Planté-Bordeneuve, Hollis Lin, Jared Gollob, Sonalee Agarwal, Marissa Betts, Kyle Fahrbach, Madhura Chitnis & Michael Polydefkis. (2019) An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy 20:4, pages 473-481.
Read now
Read now
Nobuhiko Ohashi, Minori Kodaira, Hiroshi Morita & Yoshiki Sekijima. (2019) Electrophysiological demyelinating features in hereditary ATTR amyloidosis. Amyloid 26:1, pages 15-23.
Read now
Read now
Jonah Rubin, Julissa Alvarez, Sergio Teruya, Adam Castano, Ronald A. Lehman, Mark Weidenbaum, Jeffrey A. Geller, Stephen Helmke & Mathew S. Maurer. (2017) Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?. Amyloid 24:4, pages 224-228.
Read now
Read now
Articles from other publishers (29)
Amir Dori, Michael Arad, Yishay Wasserstrum, Arthur Pollak, Vera Nikitin, Merav Ben‐David, Jana Shamash, Ayelet Hashachar Nahum, Efrat Shavit‐Stein, Liran Domachevsky, Rafael Kuperstein, Dan Dominissini, Natalia Shelestovich, Menachem Sadeh, Elon Pras & Lior Greenbaum. (2023)
Ser77Tyr
transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features
. Annals of Clinical and Translational Neurology 10:4, pages 553-567.
Crossref
Crossref
M. Masingue, G. Fernández-Eulate, R. Debs, C. Tard, C. Labeyrie, S. Leonard-Louis, C.-M. Dhaenens, M.A. Masson, P. Latour & T. Stojkovic. (2023) Strategy for genetic analysis in hereditary neuropathy. Revue Neurologique 179:1-2, pages 10-29.
Crossref
Crossref
Jose Nativi-Nicolau, Nowell M Fine, José Thomás Ortiz-Pérez, Duncan Brown, Montserrat Vera-Llonch, Sheila R Reddy, Eunice Chang & Marian H Tarbox. (2022) Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis. Journal of Comparative Effectiveness Research 11:14, pages 1031-1044.
Crossref
Crossref
Masahiro Ando, Yujiro Higuchi, Junhui Yuan, Akiko Yoshimura, Takaki Taniguchi, Fumikazu Kojima, Yutaka Noguchi, Takahiro Hobara, Mika Takeuchi, Jun Takei, Yu Hiramatsu, Yusuke Sakiyama, Akihiro Hashiguchi, Yuji Okamoto, Jun Mitsui, Hiroyuki Ishiura, Shoji Tsuji & Hiroshi Takashima. (2022) Comprehensive Genetic Analyses of Inherited Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. Biomedicines 10:7, pages 1546.
Crossref
Crossref
Takaki Taniguchi, Masahiro Ando, Yuji Okamoto, Akiko Yoshimura, Yujiro Higuchi, Akihiro Hashiguchi, Nozomu Matsuda, Mamoru Yamamoto, Eisuke Dohi, Makoto Takahashi, Masanao Yoshino, Taichi Nomura, Masaaki Matsushima, Ichiro Yabe, Yui Sanpei, Hiroyuki Ishiura, Jun Mitsui, Masanori Nakagawa, Shoji Tsuji & Hiroshi Takashima. (2022) Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments. Journal of Human Genetics 67:6, pages 353-362.
Crossref
Crossref
Jan Stassen, Pieter van der Bijl & Jeroen J. Bax. (2021) Optimizing 99mTc-DPD scintigraphy: Adding value to the diagnosis and treatment of cardiac transthyretin amyloidosis. Journal of Nuclear Cardiology 28:6, pages 2497-2499.
Crossref
Crossref
Barry J. Maron, Martin S. Maron, Mathew S. Maurer, Ethan J. Rowin, Bradley A. Maron & Nazzareno Galiè. (2021) Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association 10:20.
Crossref
Crossref
Mark H Rozenbaum, Samuel Large, Rahul Bhambri, Michelle Stewart, Robert Young, Alexander van Doornewaard, Noel Dasgupta, Ahmad Masri & Jose Nativi-Nicolau. (2021) Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. Journal of Comparative Effectiveness Research 10:11, pages 927-938.
Crossref
Crossref
Michele Vecchio, Rita Chiaramonte, Marcello Romano, Piero Pavone, Giuseppe Musumeci & Giulia Letizia Mauro. (2020) A Systematic Review of Pharmacologic and Rehabilitative Treatment of Small Fiber Neuropathies. Diagnostics 10:12, pages 1022.
Crossref
Crossref
Valentina Loconte, Michele Cianci, Ilaria Menozzi, Davide Sbravati, Francesco Sansone, Alessandro Casnati & Rodolfo Berni. (2020) Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. Bioorganic Chemistry 103, pages 104144.
Crossref
Crossref
Tomonori Ishii, Yoko Hirano, Noriko Matsumoto, Ami Takata, Yoshiki Sekijima, Mitsuharu Ueda & Yukio Ando. (2020) Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance. Clinical Therapeutics 42:9, pages 1728-1737.e6.
Crossref
Crossref
Rita Chiaramonte, Marcello Romano & Michele Vecchio. (2020) A Systematic Review of the Diagnostic Methods of Small Fiber Neuropathies in Rehabilitation. Diagnostics 10:9, pages 613.
Crossref
Crossref
Héctor Cristóbal Gutiérrez, Ana Lara Pelayo-Negro, David Gómez Gómez, Miguel Ángel Martín Vega & Marta Valero Domínguez. (2020) Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. European Journal of Hospital Pharmacy 27:4, pages 194-201.
Crossref
Crossref
Francesca Magrinelli, Gian Maria Fabrizi, Lucio Santoro, Fiore Manganelli, Giampietro Zanette, Tiziana Cavallaro & Stefano Tamburin. (2020) Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Nicole K. Bart, Liza Thomas, Dariusz Korczyk, John J. Atherton, Graeme J. Stewart & Diane Fatkin. (2020) Amyloid Cardiomyopathy. Heart, Lung and Circulation 29:4, pages 575-583.
Crossref
Crossref
Bryan Paul Traynor, Aamir Shamsi & Victor Voon. (2019) Multi-modality imaging in transthyretin amyloid cardiomyopathy. World Journal of Cardiology 11:11, pages 266-276.
Crossref
Crossref
Márcia Waddington Cruz. (2019) Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clinical Autonomic Research 29:S1, pages 19-24.
Crossref
Crossref
Yvette N. Lamb & Emma D. Deeks. (2019) Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs 79:8, pages 863-874.
Crossref
Crossref
Yinan ZhaoYanguo XinZhuyin SongZhiyi HeWenyu Hu. (2019) Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis. Journal of Clinical Neurology 15:1, pages 108.
Crossref
Crossref
H.‐W. Kan, H. Chiang, W.‐M. Lin, I.‐S. Yu, S.‐W. Lin & S.‐T. Hsieh. (2018) Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser. Neuropathology and Applied Neurobiology 44:7, pages 673-686.
Crossref
Crossref
Teresa CoelhoMónica InêsIsabel ConceiçãoMarta SoaresMamede de CarvalhoJoão Costa. (2018) Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 91:21.
Crossref
Crossref
I. Conceição, B. Miranda, J. Castro & M. de Carvalho. (2018) Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. European Journal of Neurology 25:11, pages 1320-e115.
Crossref
Crossref
Mathew S. MaurerJeffrey H. SchwartzBalarama GundapaneniPerry M. ElliottGiampaolo MerliniMarcia Waddington-CruzArnt V. KristenMartha GroganRonald WittelesThibaud DamyBrian M. DrachmanSanjiv J. ShahMazen HannaDaniel P. JudgeAlexandra I. BarsdorfPeter HuberTerrell A. PattersonSteven RileyJennifer SchumacherMichelle StewartMarla B. SultanClaudio Rapezzi. (2018) Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine 379:11, pages 1007-1016.
Crossref
Crossref
Marcus Vinicius Pinto, Amilton Antunes Barreira, Acary Souza Bulle, Marcos Raimundo Gomes de Freitas, Marcondes Cavalcante França Jr, Francisco de Assis Aquino Gondim, Carlo Domenico Marrone, Wilson Marques Jr, Osvaldo J. M. Nascimento, Francisco Tellechea Rotta, Camila Pupe & Márcia Waddington-Cruz. (2018) Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arquivos de Neuro-Psiquiatria 76:9, pages 609-621.
Crossref
Crossref
Lina Nilsson, Annelie Pamrén, Tohidul Islam, Kristoffer Brännström, Solmaz A. Golchin, Nina Pettersson, Irina Iakovleva, Linda Sandblad, Anna L. Gharibyan & Anders Olofsson. (2018) Transthyretin Interferes with Aβ Amyloid Formation by Redirecting Oligomeric Nuclei into Non-Amyloid Aggregates. Journal of Molecular Biology 430:17, pages 2722-2733.
Crossref
Crossref
Scot Walker. (2018) New Medications in the Treatment of Hereditary Transthyretin Amyloidosis. Hospital Pharmacy 53:4, pages 236-238.
Crossref
Crossref
Daniel Serrano, Christopher B. Atzinger & Marc F. Botteman. (2018) Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches. Neurology and Therapy 7:1, pages 141-154.
Crossref
Crossref
B. K. Gundapaneni, M. B. Sultan, D. J. Keohane & J. H. Schwartz. (2017) Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. European Journal of Neurology 25:3, pages 464-468.
Crossref
Crossref
Ana L. Mora, Mauricio Rojas, Annie Pardo & Moises Selman. (2017) Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nature Reviews Drug Discovery 16:11, pages 755-772.
Crossref
Crossref